Testing HOPE treatment to prevent liver cancer return after transplant
Part of Cancer, Digestive system clinical trials.
This study tests a special way of preserving donated livers, called HOPE, to see if it lowers the chance of liver cancer coming back after a liver transplant. If you have liver cancer and are waiting for a transplant, this trial might be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are listed for a liver transplant because of liver cancer (HCC)
- Your liver cancer diagnosis is confirmed by MRI, CT scan, or biopsy
- Your cancer is within certain size and number limits (the 'up-to-seven' criteria) or has been reduced to meet those limits with prior treatment
- You are able to give written consent to join the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special machine that keeps donated livers healthy before they're transplanted. It aims to improve transplant success and help more people receive a liver.
This study looks at how well people do in the long run after liver transplant using donor livers that were preserved in a specific machine called DHOPE for more than 4 hours. It may help doctors understand whether this preservation method leads to better transplant outcomes over time.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial studies whether a blood test can predict if liver cancer comes back after surgery or ablation, and whether an immunotherapy drug (PD-1 inhibitor) can help prevent recurrence. It may help guide treatment to keep the cancer from returning.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This study tests a special way to preserve donated livers before transplant to see if it reduces the chance of liver cancer coming back after surgery.
Hear when a new Liver Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.